Newegg Commerce Inc vs Viatris Inc — how do they compare? Newegg Commerce Inc trades at $11.7 (market cap $243.30M), while Viatris Inc trades at $17.62 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 82.3× Newegg Commerce Inc's market cap, and Viatris Inc pays a 2.75% dividend while Newegg Commerce Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Newegg Commerce Inc for 14 Days and Viatris Inc for 57 Days on average.
| NEGG | VTRS | |
|---|---|---|
Market Cap | $243.30M | $20.03B |
Volume | 41,252 | 14,109,977 |
Sector | Consumer Cyclical | Health |
52-Week High | $92.74 | $18.27 |
52-Week Low | $11.49 | $9.74 |
Typical Hold Time | 14 Days | 57 Days |
Enterprise Value | $213.53M | $32.15B |
Dividend Yield | — | 2.75% |
Signals from Pluang's Aura AI — not financial advice
NEGG trades at $11.69, down 2.66% today, with a bearish technical signal from moving averages but oversold RSI readings. The company shows improving fundamentals with revenue stabilizing around $1.4B and net losses narrowing significantly from -$59M in 2023 to -$4.88M in 2025. Recent earnings beats and strategic partnerships with Western Digital and HPE highlight operational progress, though negative operating cash flow and insider selling present concerns.
The outlook remains mixed with improving profitability trends but significant execution risks. Valuation appears reasonable with P/S of 0.18x, but analyst consensus target of $7.75 suggests 34% downside. Key risks include competitive e-commerce pressures and the need to sustain recent operational improvements amid challenging market conditions.
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →